acoramidis
acoramidis: 5 clinical trials tracked.
acoramidis evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about acoramidis, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trials (5)
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Primary endpoint: To evaluate the long-term safety and tolerability of acoramidis in participants with newly diagnosed ATTR-CM
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Primary endpoint: To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM.
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Primary endpoint: Time to development of ATTR (ATTR-CM or ATTR-PN, whichever occurs first; centrally adjudicated)
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Primary endpoint: Incidence of treatment-emergent Adverse Events [Safety and Tolerability]
A Phase 1, Randomized, Open-Label, 2-Period, 2-Sequence, 2-Way Crossover Study to Assess the Effect of Food on the Single Dose Pharmacokinetics of Acoramidis in Healthy Participants
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) Of Acoramidis: Fed (Test) Versus Fasted (Reference) Conditions